Go Pro
→ China Declares War (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.18
-2.5%		$1.04
$0.56
▼
$2.98
$122.01M1.526.58 million shs5.00 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.94
+6.2%		$8.48
$6.20
▼
$11.97
$1.47B2.463.68 million shs10.44 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-2.48%+8.26%+11.32%-12.59%-36.22%
Novavax, Inc. stock logo
NVAX
Novavax
+6.18%+11.06%+13.02%-2.93%+2.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.18
-2.5%		$1.04
$0.56
▼
$2.98
$122.01M1.526.58 million shs5.00 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.94
+6.2%		$8.48
$6.20
▼
$11.97
$1.47B2.463.68 million shs10.44 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-2.48%+8.26%+11.32%-12.59%-36.22%
Novavax, Inc. stock logo
NVAX
Novavax
+6.18%+11.06%+13.02%-2.93%+2.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.75
Moderate Buy$3.17168.36% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.33
Hold$14.0056.60% Upside

Current Analyst Ratings Breakdown

Latest NVAX and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/13/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
8/13/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Positive$1.80 ➝ $3.00
8/12/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/4/2026
Novavax, Inc. stock logo
NVAX
Novavax
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/3/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$4.00
7/29/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/1/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/16/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$60K2,033.53N/AN/A$0.04 per share29.50
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.31$3.51 per share2.55($1.16) per share-7.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$84.95M-$0.91N/AN/AN/AN/A-669.94%-73.97%11/10/2026 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$1.52N/AN/AN/A-59.87%-14.82%-13.35%11/5/2026 (Estimated)

Latest NVAX and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.2167-$0.07+$0.1467-$0.07$0.53 millionN/A
8/6/2026Q2 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3798-$0.32+$0.0598-$0.32$52.51 million$56.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
1.00
1.00
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.33
2.30

Institutional Ownership

CompanyInstitutional Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.70%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
320103.40 million101.64 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990164.95 million162.31 millionOptionable

Recent News About These Companies

Novavax (NASDAQ:NVAX) Trading Up 6.9% - Still a Buy?
August 21 at 12:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novavax-nasdaqnvax-trading-up-69-still-a-buy-2026-08-21/
Stock Traders Purchase Large Volume of Novavax Call Options (NASDAQ:NVAX)
August 21 at 1:20 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973150
Novavax stock moves higher Wednesday: What's driving the action?
August 20 at 12:51 PM  |  msn.comhttps://www.msn.com/en-us/money/news/novavax-stock-moves-higher-wednesday-whats-driving-the-action/ar-AA2auLU4
Novavax (NASDAQ:NVAX) Stock Price Down 6.8% - What's Next?
August 20 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novavax-nasdaqnvax-stock-price-down-68-whats-next-2026-08-20/
Recursion, Novavax and CRISPR stocks trending in pre-market—here's why
August 20 at 7:50 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/recursion-novavax-and-crispr-stocks-trending-in-pre-market-here-s-why/ar-AA2ay4BP
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
August 20 at 6:30 AM  |  benzinga.comhttps://www.benzinga.com/markets/equities/26/08/61322461/recursion-novavax-crispr-stocks-premarket-cancer-therapy-rally
BioNTech Stock Surges 22% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.
August 19 at 10:54 PM  |  finance.yahoo.comhttps://finance.yahoo.com/m/54926def-c88c-3783-9c11-a0a6c00b7bed/biontech-stock-surges-22%25-on.html
Novavax (NVAX) Shares Skyrocket, What You Need To Know
August 19 at 10:54 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novavax-nvax-shares-skyrocket-know-215002669.html
How Moderna’s Cancer Breakthrough Reversed Its Fortunes and Revived the Stock
August 19 at 5:53 PM  |  finance.yahoo.comhttps://finance.yahoo.com/m/46ee6bad-a1ca-3803-901e-a9bb055a64e6/how-moderna%E2%80%99s-cancer.html
Investors Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX)
August 19 at 1:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/investors-buy-large-volume-of-call-options-on-novavax-nasdaqnvax-2026-08-19/
Is Sanofi (ENXTPA:SAN) Reasonable After A 10% Three Year Slide?
August 19 at 12:52 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/sanofi-enxtpa-san-reasonable-10-121031569.html
Moderna’s Cancer Breakthrough Sends the Stock Soaring 84%
August 19 at 12:52 PM  |  finance.yahoo.comhttps://finance.yahoo.com/m/46ee6bad-a1ca-3803-901e-a9bb055a64e6/moderna%E2%80%99s-cancer-breakthrough.html
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
August 19 at 12:50 PM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/08/61308404/novavax-stock-moves-higher-wednesday-whats-driving-the-action
Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Brokerages
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963459
Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novavax-inc-nasdaqnvax-given-consensus-rating-of-hold-by-analysts-2026-08-16/
Bank of America Corp DE Cuts Stock Holdings in Novavax, Inc. $NVAX
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-cuts-stock-holdings-in-novavax-inc-nvax-2026-08-12/
Novavax (NVAX) Q2 2026
August 8, 2026  |  247wallst.comhttps://247wallst.com/companies/nvax/earnings
Cantor Fitzgerald Sticks to Its Buy Rating for Novavax (NVAX)
August 8, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3736577/cantor-fitzgerald-sticks-to-its-buy-rating-for-novavax-nvax/
Novavax (NASDAQ:NVAX) Lowered to Hold Rating by Zacks Research
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novavax-nasdaqnvax-lowered-to-hold-rating-by-zacks-research-2026-08-08/
Renaissance Technologies LLC Invests $4.05 Million in Novavax, Inc. $NVAX
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-invests-405-million-in-novavax-inc-nvax-2026-08-08/
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nvax-q2-earnings-sales-beat-181800274.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.18 -0.03 (-2.48%)
As of 08/21/2026 04:00 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Novavax stock logo

Novavax NASDAQ:NVAX

$8.94 +0.52 (+6.18%)
As of 08/21/2026 04:00 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas